Zoetis, Inc. Class A Stock News

There are many dividend stocks on equity markets, but not all are attractive to income investors. Those that go beyond paying a quarterly payout but also consistently raise their dividends -- all while having robust businesses that can support their dividend programs for a long time -- are the ones income-seekers want.

My Top 15 High-Growth Dividend stocks outperformed SPY and VIG in March, posting a loss of 3.26% compared to SPY's 5.86% and VIG's 4.50%. The April 2025 list offers an average dividend yield of 1.25% and is potentially 31% undervalued, poised for strong long-term returns. Dollar cost averaging into the top 15 stocks each month shows a 68.54% success rate, with 61 out of 89 stocks leading to pos...

Shares in animal pharmaceutical company Zoetis (ZTS 0.14%) have been under a cloud since the release of the company's fourth-quarter earnings report in mid-February. The Q4 numbers were fine, but the company's revenue guidance fell short of expectations.

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, May 6, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review first quarter 2025 financial results and respond to questions from financial analysts during the call. Investors...

Zoetis is currently cheap from a historical perspective, presenting a potential buying opportunity. The company operates in a growing animal healthcare market, benefiting from trends like pet humanization and medicalization, ensuring long-term growth. ZTS has a strong track record of market outperformance, impressive margins, and a high ROIC, making it a high-quality company.

The recent divestiture of the MFA segment improves margins and returns on capital. Zoetis is focusing on more profitable segments like genetics and companion animals. The recently updated Librela label includes adverse effects and urges practitioners to discuss potential adverse reactions with clients.

Zoetis Inc. (NYSE:ZTS ) Barclays 27th Annual Global Healthcare March 11, 2025 10:30 AM ET Company Participants Wetteny Joseph - Chief Financial Officer Conference Call Participants Balaji Prasad - Barclays Balaji Prasad Good morning, everyone. Thanks for joining us at the Barclays Healthcare Conference.

The SPDR S&P 500 ETF Trust stumbled in February but managed to maintain a positive return in 2025. The Top 15 dividend growth stocks for March 2025 offer an average dividend yield of 1.13% and appear to be about 25% undervalued based on dividend yield theory. Since its inception in September 2020, the watch list has achieved a 10.63% compound annual growth rate.